Novel anti-HIV-1 activity produced by conjugating unsulfated dextran with polyL-lysine

Antiviral Res. 2012 Apr;94(1):89-97. doi: 10.1016/j.antiviral.2012.02.011. Epub 2012 Mar 3.

Abstract

A conjugate of polyL-lysine (PLL) with unsulfated dextran produced by reductive amination was found to have remarkable anti-HIV-1 activity against both the macrophage-tropic R5 virus Ba-L and T-cell line tropic X4 virus IIIB strains, although neither PLL nor dextran has such activity. The conjugate is a pseudoproteoglycan (pseudoPG) that simulates the structure of a proteoglycan. Conjugation with dextran was found to produce an antiviral effect in three kinds of assay systems including a human CD4(+) T-cell line, and the pseudoPG synthesized using 10 kDa PLL and 10 kDa dextran showed EC(50) 4-40 times lower than that of sulfated dextran or heparin against Ba-L and EC(50) equal to that against IIIB, indicating that PLL-dextran (PLL-Dex) was more effective against R5 virus than sulfated polysaccharides. PLL-Dex significantly suppressed a clinically isolated R5 virus from primary peripheral blood mononuclear cells. PLL-Dex interacted with the virus during adsorption to the cell and also decreased virus entry into the cell, suggesting PLL-Dex has multiple preventive mechanisms against HIV-1.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-HIV Agents / chemistry
  • Anti-HIV Agents / pharmacology*
  • Cell Line
  • Dextrans / chemistry*
  • Dextrans / pharmacology
  • Female
  • HIV Infections / drug therapy*
  • HIV Infections / virology
  • HIV-1 / drug effects*
  • HIV-1 / physiology
  • Humans
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Polylysine / chemistry
  • Polylysine / pharmacology*
  • Proteoglycans / chemistry
  • Proteoglycans / pharmacology*
  • Virus Internalization / drug effects
  • Virus Replication / drug effects

Substances

  • Anti-HIV Agents
  • Dextrans
  • Proteoglycans
  • Polylysine